8-K Announcements
6Material company update
Apr 20, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Feb 26, 2026·SEC
Neurogene Inc.(NGNE)Earnings, Financials & Key Ratios
NGNE•NASDAQ
$31.26
$488M mkt cap·Price updated May 7, 2026
AboutNeurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.Show more
- Revenue$0-100.0%
- EBITDA-$103M-30.2%
- Net Income-$90M-20.2%
- EPS (Diluted)-4.24+0.9%
- ROE-31.41%-3.8%
- ROIC-43.35%+15.9%
- Debt/Equity0.04-6.7%
- Interest Coverage-20641.60-229.7%
NGNE Key Insights
Neurogene Inc. (NGNE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 22.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 20.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NGNE Price & Volume
Neurogene Inc. (NGNE) stock price & volume — 10-year historical chart
Loading chart...
NGNE Growth Metrics
Neurogene Inc. (NGNE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.83%
Return on Capital
10 Years-34.2%
5 Years-39.26%
3 Years-34.46%
Last Year-34.82%
NGNE Recent Earnings
Neurogene Inc. (NGNE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
Mar 24, 2026EPS
$1.12
Est $1.24
+9.6%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.99
Est $1.26
+21.4%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$1.05
Est $1.15
+8.7%
Revenue
—
Q2 2025
May 9, 2025EPS
$1.08
Est $1.05
-2.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $1.12vs $1.24+9.6% | — |
| Q4 2025 | Nov 13, 2025 | $0.99vs $1.26+21.4% | — |
| Q3 2025 | Aug 11, 2025 | $1.05vs $1.15+8.7% | — |
| Q2 2025 | May 9, 2025 | $1.08vs $1.05-2.9% | — |
Based on last 12 quarters of dataView full earnings history →
NGNE Peer Comparison
Neurogene Inc. (NGNE) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ARQT | 2.58B | 20.66 | -158.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% |
Compare NGNE vs Peers
Neurogene Inc. (NGNE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NGNE Income Statement
Neurogene Inc. (NGNE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 25M | 0 | 0 | 0 | 0 | 0 | 925K | 0 |
| Revenue Growth % | - | - | -100% | - | - | - | - | - | -100% |
| Cost of Goods Sold | 0 | 0 | 340K | 1.82M | 42.26M | 3.2M | 3.26M | 3.25M | 3.19M |
| COGS % of Revenue | - | - | - | - | - | - | - | 351.03% | - |
| Gross Profit | 0▲ 0% | 25M▲ 0% | -340K▼ 101.4% | -1.82M▼ 435.6% | -42.26M▼ 2220.9% | -3.2M▲ 92.4% | -3.26M▼ 2.1% | -2.32M▲ 28.8% | -3.19M▼ 37.5% |
| Gross Margin % | - | 100% | - | - | - | - | - | -251.03% | - |
| Gross Profit Growth % | - | - | -101.36% | -435.59% | -2220.92% | 92.44% | -2.07% | 28.82% | -37.47% |
| Operating Expenses | 51.12M | 48.52M | 24.1M | 39.73M | 8.27M | 53.32M | 52.32M | 80.28M | 100.02M |
| OpEx % of Revenue | - | 194.1% | - | - | - | - | - | 8679.24% | - |
| Selling, General & Admin | 14.85M | 15.73M | 17.79M | 15.39M | 8.27M | 9.01M | 11.19M | 22.61M | 25.13M |
| SG&A % of Revenue | - | 62.94% | - | - | - | - | - | 2444.65% | - |
| Research & Development | 36.27M | 32.79M | 6.32M | 24.34M | 42.26M | 47.51M | 44.39M | 60.92M | 75.01M |
| R&D % of Revenue | - | 131.16% | - | - | - | - | - | 6585.62% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -42.26M | -3.2M | -3.26M | -3.25M | 0 |
| Operating Income | -51.12M▲ 0% | -23.52M▲ 54.0% | -24.44M▼ 3.9% | -41.55M▼ 70.0% | -50.53M▼ 21.6% | -56.52M▼ 11.8% | -55.58M▲ 1.7% | -82.61M▼ 48.6% | -103.21M▼ 24.9% |
| Operating Margin % | - | -94.1% | - | - | - | - | - | -8930.27% | - |
| Operating Income Growth % | -35.79% | 53.98% | -3.91% | -70% | -21.61% | -11.84% | 1.65% | -48.62% | -24.94% |
| EBITDA | -50.18M | -31.58M | -24.1M | -39.73M | -49.59M | -53.32M | -52.29M | -79.36M | -103.33M |
| EBITDA Margin % | - | -126.32% | - | - | - | - | - | -8579.24% | - |
| EBITDA Growth % | -35.62% | 37.06% | 23.68% | -64.85% | -24.8% | -7.53% | 1.94% | -51.78% | -30.2% |
| D&A (Non-Cash Add-back) | 0 | 0 | 340K | 1.82M | 947K | 3.2M | 3.3M | 3.25M | 0 |
| EBIT | -50.18M | -31.58M | -69.44M | -33.28M | -50.53M | -55.19M | -55.58M | -75.13M | -103.21M |
| Net Interest Income | 994K | 1.56M | 1.54M | 490K | 19K | 1.33M | 2.94M | 8.46M | 11.54M |
| Interest Income | 998K | 1.56M | 1.54M | 490K | 19K | 1.34M | 2.95M | 8.47M | 11.55M |
| Interest Expense | 4K | 4K | 1K | 0 | 0 | 2K | 12K | 12K | 5K |
| Other Income/Expense | 936K | -8.06M | -45M | 8.28M | 17K | 1.33M | 19.27M | 7.46M | 12.86M |
| Pretax Income | -50.18M▲ 0% | -31.59M▲ 37.1% | -69.44M▼ 119.9% | -33.28M▲ 52.1% | -50.52M▼ 51.8% | -55.19M▼ 9.2% | -36.32M▲ 34.2% | -75.14M▼ 106.9% | -90.35M▼ 20.2% |
| Pretax Margin % | - | -126.34% | - | - | - | - | - | -8123.68% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -50.18M▲ 0% | -31.59M▲ 37.1% | -69.44M▼ 119.9% | -33.28M▲ 52.1% | -50.52M▼ 51.8% | -55.19M▼ 9.2% | -36.32M▲ 34.2% | -75.14M▼ 106.9% | -90.35M▼ 20.2% |
| Net Margin % | - | -126.34% | - | - | - | - | - | -8123.68% | - |
| Net Income Growth % | -35.62% | 37.06% | -119.86% | 52.08% | -51.81% | -9.25% | 34.2% | -106.91% | -20.24% |
| Net Income (Continuing) | -50.18M | -31.59M | -69.44M | -33.28M | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.14▲ 0% | -1.34▲ 37.4% | -2.57▼ 91.8% | -0.64▲ 75.1% | -0.92▼ 43.8% | -4.30▼ 367.4% | -2.83▲ 34.2% | -4.28▼ 51.2% | -4.24▲ 0.9% |
| EPS Growth % | -9.18% | 37.38% | -91.79% | 75.1% | -43.75% | -367.39% | 34.19% | -51.24% | 0.93% |
| EPS (Basic) | -2.14 | -1.34 | -2.57 | -0.64 | -0.92 | -4.30 | -2.83 | -4.28 | -4.24 |
| Diluted Shares Outstanding | 23.45M | 23.52M | 27.03M | 51.83M | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
| Basic Shares Outstanding | 23.45M | 23.52M | 27.03M | 51.83M | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NGNE Balance Sheet
Neurogene Inc. (NGNE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 108.83M | 77.17M | 143.6M | 194.52M | 73.96M | 84.72M | 200.35M | 315.92M | 271.77M |
| Cash & Short-Term Investments | 108.08M | 76.93M | 143.09M | 192.56M | 70.54M | 82.02M | 197.16M | 312.4M | 269.01M |
| Cash Only | 52.03M | 76.93M | 143.09M | 192.56M | 70.54M | 82.02M | 148.21M | 136.59M | 103.84M |
| Short-Term Investments | 56.05M | 0 | 0 | 0 | 0 | 0 | 48.95M | 175.82M | 165.17M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 790K | 0 | 600K | 648K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | 255.7 | - |
| Inventory | 0 | 0 | 0 | 0 | 1.91M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 16.52 | - | - | - | - |
| Other Current Assets | 740K | 237K | 503K | 1.97M | -1.2M | 1.62M | 1.09M | 981K | 2.76M |
| Total Non-Current Assets | 1.5M | 453K | 3.43M | 16M | 27.53M | 24.55M | 22.23M | 19.81M | 16.83M |
| Property, Plant & Equipment | 905K | 400K | 2.83M | 13.72M | 27.53M | 24.55M | 20.95M | 18.49M | 15.46M |
| Fixed Asset Turnover | - | 62.50x | - | - | - | - | - | 0.05x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 567K | 347K | 128K | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 878K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 599K | 53K | 30K | 1.93M | -1.01M | 0 | 1.27M | 1.31M | 1.37M |
| Total Assets | 110.33M▲ 0% | 77.62M▼ 29.6% | 147.02M▲ 89.4% | 210.52M▲ 43.2% | 101.49M▼ 51.8% | 109.27M▲ 7.7% | 222.57M▲ 103.7% | 335.73M▲ 50.8% | 288.6M▼ 14.0% |
| Asset Turnover | - | 0.32x | - | - | - | - | - | 0.00x | - |
| Asset Growth % | -28.53% | -29.65% | 89.42% | 43.19% | -51.79% | 7.66% | 103.7% | 50.84% | -14.04% |
| Total Current Liabilities | 10.96M | 4.63M | 4.74M | 7.89M | 10.86M | 6.65M | 22.97M | 15.16M | 16.41M |
| Accounts Payable | 0 | 702K | 1.6M | 1.32M | 5.63M | 625K | 2.6M | 1.34M | 1.95M |
| Days Payables Outstanding | - | - | 1.72K | 265.18 | 48.62 | 71.38 | 290.48 | 150.18 | 223.32 |
| Short-Term Debt | 0 | 0 | 618K | 708K | 1.22M | 0 | 0 | 3M | 3.06M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.4M | 3.92M | 1.28M | 2.61M | 132K | 167K | 6.71M | 1.43M | 11.39M |
| Current Ratio | 9.93x | 16.68x | 30.28x | 24.66x | 6.81x | 12.74x | 8.72x | 20.84x | 16.56x |
| Quick Ratio | 9.93x | 16.68x | 30.28x | 24.66x | 6.64x | 12.74x | 8.72x | 20.84x | 16.56x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 486K | 319K | 593K | 11.41M | 182.51M | 3.99M | 13.58M | 10.2M | 7.31M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.83M |
| Capital Lease Obligations | 33K | 6K | 593K | 11.41M | 4.6M | 3.99M | 13.37M | 9.43M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | -1 | 0 | 0 | 177.91M | 0 | 203K | 769K | 479K |
| Total Liabilities | 11.44M | 4.95M | 5.34M | 19.3M | 193.36M | 10.64M | 36.55M | 25.36M | 23.72M |
| Total Debt | 33K | 6K | 1.21M | 12.12M | 6.43M | 4.69M | 16.25M | 12.43M | 9.89M |
| Net Debt | -52M | -76.92M | -141.88M | -180.43M | -64.11M | -77.33M | -131.96M | -124.16M | -93.95M |
| Debt / Equity | 0.00x | 0.00x | 0.01x | 0.06x | - | 0.05x | 0.09x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -12544.75x | -7895.25x | -69441.00x | - | - | -27593.50x | -4631.92x | -6261.00x | -20641.60x |
| Total Equity | 98.89M▲ 0% | 72.67M▼ 26.5% | 141.69M▲ 95.0% | 191.22M▲ 35.0% | -91.88M▼ 148.0% | 98.63M▲ 207.3% | 186.02M▲ 88.6% | 310.38M▲ 66.8% | 264.89M▼ 14.7% |
| Equity Growth % | -31.64% | -26.51% | 94.97% | 34.96% | -148.05% | 207.35% | 88.61% | 66.85% | -14.66% |
| Book Value per Share | 4.22 | 3.09 | 5.24 | 3.69 | -1.67 | 7.69 | 14.51 | 17.67 | 12.51 |
| Total Shareholders' Equity | 98.89M | 72.67M | 141.69M | 191.22M | -91.88M | 98.63M | 186.02M | 310.38M | 264.89M |
| Common Stock | 0 | 0 | 0 | 0 | 1K | 0 | 0 | 0 | 0 |
| Retained Earnings | -198.5M | -230.09M | -299.53M | -332.81M | -95.65M | -150.84M | -187.15M | -262.3M | -352.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -70K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NGNE Cash Flow Statement
Neurogene Inc. (NGNE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -44.72M | -31.58M | -15.39M | -24.57M | -46.4M | -52.82M | -51.42M | -70.6M | -77.17M |
| Operating CF Margin % | - | -126.31% | - | - | - | - | - | -7632.76% | - |
| Operating CF Growth % | -47.95% | 29.39% | 51.25% | -59.64% | -88.81% | -13.84% | 2.65% | -37.3% | -9.31% |
| Net Income | -50.18M | -31.59M | -8.1M | -33.28M | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
| Depreciation & Amortization | 0 | 0 | 340K | 1.82M | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 896K | 1.25M | 1.42M | 8.32M | 14.18M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -105K | 0 | 0 |
| Other Non-Cash Items | 4.55M | 5.44M | -5.68M | 5.92M | 679K | 608K | -15.69M | -1.06M | -4.37M |
| Working Capital Changes | 917K | -5.43M | -1.95M | 966K | 1.59M | -2.69M | -4.02M | -5.96M | 268K |
| Change in Receivables | 0 | 0 | 290K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 2.98M | -3.61M | 667K | -77K | 627K |
| Cash from Investing | 64.01M | 55.95M | -688K | -2.22M | -18.37M | -2.23M | 25.64M | -125.26M | 14M |
| Capital Expenditures | -494K | -49K | -879K | -2.22M | -18.37M | -2.23M | -321K | -808K | -1.18M |
| CapEx % of Revenue | - | 0.2% | - | - | - | - | - | 87.35% | - |
| Acquisitions | 0 | 0 | 191K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 20.96M | 0 | 0 |
| Cash from Financing | 423K | 570K | 82.24M | 77.14M | 51.06M | 66.53M | 92.48M | 184.07M | 30.43M |
| Debt Issued (Net) | -15K | -32K | -9K | -49K | 0 | -1K | -29K | -52K | -61K |
| Equity Issued (Net) | 438K | 602K | 82.25M | 77.18M | 50.78M | 66.46M | 92.34M | 189.59M | 30.49M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 287K | 73K | 168K | -5.47M | 0 |
| Net Change in Cash | 19.73M▲ 0% | 24.9M▲ 26.2% | 66.17M▲ 165.8% | 49.46M▼ 25.2% | -13.71M▼ 127.7% | 11.48M▲ 183.7% | 66.7M▲ 481.1% | -11.79M▼ 117.7% | -32.74M▼ 177.6% |
| Free Cash Flow | -45.21M▲ 0% | -31.63M▲ 30.0% | -16.27M▲ 48.5% | -26.79M▼ 64.7% | -64.77M▼ 141.7% | -55.05M▲ 15.0% | -51.74M▲ 6.0% | -71.41M▼ 38.0% | -78.36M▼ 9.7% |
| FCF Margin % | - | -126.5% | - | - | - | - | - | -7720.11% | - |
| FCF Growth % | -46.13% | 30.05% | 48.55% | -64.65% | -141.73% | 15% | 6.01% | -38.01% | -9.73% |
| FCF per Share | -1.93 | -1.34 | -0.60 | -0.52 | -1.18 | -4.29 | -4.03 | -4.07 | -3.70 |
| FCF Conversion (FCF/Net Income) | 0.89x | 1.00x | 0.22x | 0.74x | 0.92x | 0.96x | 1.42x | 0.94x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 2K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NGNE Key Ratios
Neurogene Inc. (NGNE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -29.24% | -41.21% | -36.82% | -64.79% | -19.99% | -101.7% | -1634.75% | -25.52% | -30.28% | -31.41% |
| Return on Invested Capital (ROIC) | -31.12% | -48.14% | -82.76% | - | -588.75% | - | - | -110.63% | -51.57% | -43.35% |
| Gross Margin | - | - | 100% | - | - | - | - | - | -251.03% | - |
| Net Margin | - | - | -126.34% | - | - | - | - | - | -8123.68% | - |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.06x | - | 0.05x | 0.09x | 0.04x | 0.04x |
| Interest Coverage | -37001.00x | -12544.75x | -7895.25x | -69441.00x | - | - | -27593.50x | -4631.92x | -6261.00x | -20641.60x |
| FCF Conversion | 0.82x | 0.89x | 1.00x | 0.22x | 0.74x | 0.92x | 0.96x | 1.42x | 0.94x | 0.85x |
| Revenue Growth | - | - | - | -100% | - | - | - | - | - | -100% |
NGNE SEC Filings & Documents
Neurogene Inc. (NGNE) SEC filings — annual & quarterly reports (10-K, 10-Q)
NGNE Frequently Asked Questions
Neurogene Inc. (NGNE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Neurogene Inc. (NGNE) saw revenue decline by 100.0% over the past year.
Neurogene Inc. (NGNE) reported a net loss of $90.4M for fiscal year 2025.
Dividend & Returns
Neurogene Inc. (NGNE) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.
Neurogene Inc. (NGNE) had negative free cash flow of $77.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More NGNE
Neurogene Inc. (NGNE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates